Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy

NCT07166094 is registered in ClinicalTrials.gov with Genmab as lead sponsor.

NCT NCT07166094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07166094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy
Lead sponsor
Genmab
Phase
Phase 3
Overall status
Recruiting
Start date
November 28, 2025
Completion date
November 30, 2029
Enrollment
660 (estimated)
Sites
177

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer, recurrent or progressive endometrial cancer